July 12th 2024
“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Drug-Free Management Tools Provide Alternatives to Opioids in Kidney Cancer
April 22nd 2023An expert from University Hospitals touches on pain management guidelines that highlight moderate evidence in support of acupuncture, reflexology, and acupressure and massage as tools to manage general pain in patients with cancer.
Value of Collaboration in Managing Patients With Metastatic RCC
Closing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.
Expert Discusses ‘Impactful’ Guidelines for Integrative Kidney Cancer Care
April 17th 2023An expert from University Hospitals highlights different guidelines penned by oncology organizations informing the integrative management of symptoms including anxiety and depression in patients with kidney cancer.
Novel Therapy in Metastatic RCC: An Evolving Treatment Landscape
Expert panelists share their perspective on novel and combination strategies being investigated in the setting of metastatic renal cell carcinoma.
Clinical Scenario 2: Favorable-Risk Metastatic Renal Cell Carcinoma
Switching focus to a second clinical scenario, key opinion leaders on metastatic renal cell carcinoma discuss the treatment landscape for favorable-risk disease.
Current Prognoses With Metastatic Renal Cell Carcinoma
Before closing out their review of the first clinical scenario, panelists consider the general state of prognoses within metastatic renal cell carcinoma.
Dose Adjusting Therapy for Patients With Metastatic Renal Cell Carcinoma
A brief review of dose hold or adjustment strategies in the setting of metastatic renal cell carcinoma and when it is appropriate to consider these options.
Metastatic Renal Cell Carcinoma: Communicating Treatment Options With Patients
Shared insight on the treatment armamentarium for metastatic renal cell carcinoma and how these options should be communicated with patients.
Clinical Scenario 1: Renal Cell Carcinoma Diagnosis and Staging
Centering discussion on a clinical scenario of metastatic renal cell carcinoma, expert panelists reflect on optimal diagnosis and stratification methods in this setting.